The National Multiple Sclerosis Society funds research in a range of scientific areas including immune mechanisms, genetics, nerve regeneration and symptom managements. The agreement with Amplimmune is a part of the Society's Fast Forward initiative through which Fast Forward will partner with young innovative biotechnology and pharmaceutical companies to develop treatments, diagnostics, medical devices, and related technologies to treat, reverse and ultimately cure MS. Under the terms of the agreement, Fast Forward will provide Amplimmune with funds to support preclinical development of AMP-110. In consideration, Fast Forward will receive warrants to purchase shares of the company.
**NOTE TO EDITORS: Fast Forward's partnership with Amplimmune continues to expand its role in spurring MS drug development in the emerging biotech market and follows on its successful alliances with Apitope International to fund a proof of principle clinical trial for a peptide therapeutic vaccine and with Provid Pharmaceuticals to develop a novel compound intended to redirect abnormal immune response. It also builds on Fast Forward's $19 million collaborative partnership with EMD Serono to accelerate innovation and commercial development of MS therapies through a group of soon to be determined, mutually agreed upon seed-to-early stage projects. Emerging biotechnology companies face many challenges in the current economy, and Fast Forward is determined to deploy its resources to spearhead the continued development of promising MS therapies.
About Fast Forward, LLC
Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward will accomplis
Copyright©2009 Vocus, Inc.
All rights reserved